Antiarrhythmic activity of potassium canrenoate in man.
The efficacy of potassium canrenoate in suppressing frequent ventricular premature depolarizations and ventricular bigeminal and trigeminal rhythms thought to be due to digitalis overdose was studied in seven men and five women (average age, 54.5 years). A mean dose of 525 mg. (1.31 mEq.) of potassium canrenoate administered intravenously effectively suppressed the ventricular rhythm disturbances in eight of the 12 patients for from several minutes to 4 hours. The mean serum digoxin level determined in seven patients was greater than 2.3 ng. per milliliter. The ability of potassium canrenoate to counteract digitalis intoxication suggests that the molecule of canrenoate is unique in the clinical setting since it shows both diuretic and antiarrhythmic properties.
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002191:Canrenoic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D004071:Digitalis Glycosides / Q000506:poisoning*; D004077:Digoxin / Q000097:blood; D004232:Diuretics / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000139:chemically induced / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D004232:Diuretics; D011245:Pregnadienes; D004077:Digoxin; D002191:Canrenoic Acid